Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ.

Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Review.

2.

MR imaging features of amyloid-related imaging abnormalities.

Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M.

AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub 2013 Apr 11.

3.

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.

Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melançon D, Morris K, Ketter N, Liu E, Brashear HR.

J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):106-12. doi: 10.1136/jnnp-2014-309493. Epub 2015 Feb 10.

4.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M.

Lancet Neurol. 2012 Mar;11(3):241-9. doi: 10.1016/S1474-4422(12)70015-7. Epub 2012 Feb 3.

5.

Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease.

Ryan NS, Lashley T, Revesz T, Dantu K, Fox NC, Morris HR.

J Alzheimers Dis. 2015;44(4):1069-74. doi: 10.3233/JAD-142325.

PMID:
25408217
6.

The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.

Martens RM, Bechten A, Ingala S, van Schijndel RA, Machado VB, de Jong MC, Sanchez E, Purcell D, Arrighi MH, Brashear RH, Wattjes MP, Barkhof F.

Eur Radiol. 2018 Mar;28(3):1215-1226. doi: 10.1007/s00330-017-5022-6. Epub 2017 Sep 27.

PMID:
28956123
7.

An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.

Barkhof F, Daams M, Scheltens P, Brashear HR, Arrighi HM, Bechten A, Morris K, McGovern M, Wattjes MP.

AJNR Am J Neuroradiol. 2013 Aug;34(8):1550-5. doi: 10.3174/ajnr.A3475. Epub 2013 Feb 22.

8.

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.

Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M, Chen X, Sur C, Parker EM, Kennedy ME.

J Alzheimers Dis. 2017;59(4):1393-1413. doi: 10.3233/JAD-170056.

9.

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.

Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, Oh J, Barakos J.

Alzheimers Dement (Amst). 2016 Mar 2;2:75-85. doi: 10.1016/j.dadm.2016.02.004. eCollection 2016.

10.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15. doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.

PMID:
23583235
11.

Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.

Heuer E, Jacobs J, Du R, Wang S, Keifer OP, Cintron AF, Dooyema J, Meng Y, Zhang X, Walker LC.

J Alzheimers Dis. 2017;57(2):519-530. doi: 10.3233/JAD-160981.

12.

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.

Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM.

J Alzheimers Dis. 2017;57(2):557-573. doi: 10.3233/JAD-160216.

PMID:
28269765
13.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.

Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW.

Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y.

14.

Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.

Bechten A, Wattjes MP, Purcell DD, Aliaga ES, Daams M, Brashear HR, Arrighi HM, Barkhof F.

J Neuroimaging. 2017 May;27(3):318-325. doi: 10.1111/jon.12422. Epub 2017 Jan 19.

PMID:
28102639
15.

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.

DiFrancesco JC, Longoni M, Piazza F.

Front Neurol. 2015 Sep 25;6:207. doi: 10.3389/fneur.2015.00207. eCollection 2015. Review.

16.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

PMID:
21784350
17.

[Aβ immunotherapy for Alzheimer's disease].

Sakai K, Yamada M.

Brain Nerve. 2013 Apr;65(4):461-8. Review. Japanese.

PMID:
23568994
18.

Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.

Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB.

J Pharmacol Exp Ther. 2010 Dec;335(3):580-8. doi: 10.1124/jpet.110.172932. Epub 2010 Sep 7.

19.

Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies.

Boncoraglio GB, Piazza F, Savoiardo M, Farina L, DiFrancesco JC, Prioni S, Tagliavini F, Parati EA, Giaccone G.

J Alzheimers Dis. 2015;45(2):363-7. doi: 10.3233/JAD-142376.

PMID:
25537009
20.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463

Supplemental Content

Support Center